Evaluation of oral acyclovir therapy

C. Fletcher, B. Bean

Research output: Contribution to journalReview article

54 Citations (Scopus)

Abstract

Acyclovir is a specific antiviral agent. The triphosphate form inhibits viral DNA replication by competing for incorporation into the replicating DNA chain or by inhibiting viral DNA polymerase. Cells not infected with herpesvirus are generally unaffected. oral acyclovir inhibits most herpes simplex virus types 1 and 2, and varicella-zoster virus at concentrations used clinically. Oral acyclovir has an average plasma half-life of three hours and is eliminated primarily by renal mechanisms. Peak plasma concentrations occur 1.5 to 2.5 hours after administration and the oral bioavailability is 15 to 30%. Acyclovir distributes into most body tissues, including vesicular fluid and the central nervous system. Oral acyclovir is effective treatment of initial and recurrent genital herpes and can suppress frequently recurring genital herpes in both immunocompetent and immunocompromised patients. It is also effective for acute herpes zoster in the immunocompetent and possibly immunocompromised patient. No role is established in either Epstein-Barr virus or cytomegalovirus infections. Oral acyclovir appears to be effective and relatively safe, nontoxic therapy when administered in doses of 1-4 g/d. Oral acyclovir represents a major therapeutic advance in the treatment of herpesvirus infections.

Original languageEnglish (US)
Pages (from-to)518-524
Number of pages7
JournalDrug Intelligence and Clinical Pharmacy
Volume19
Issue number7-8
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Acyclovir
Herpes Genitalis
Viral DNA
Immunocompromised Host
Therapeutics
Herpesviridae Infections
Epstein-Barr Virus Infections
Human Herpesvirus 3
Human Herpesvirus 2
Herpesviridae
Cytomegalovirus Infections
Herpes Zoster
Human Herpesvirus 1
DNA-Directed DNA Polymerase
DNA Replication
Biological Availability
Antiviral Agents
Oral Administration
Half-Life
Central Nervous System

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Evaluation of oral acyclovir therapy. / Fletcher, C.; Bean, B.

In: Drug Intelligence and Clinical Pharmacy, Vol. 19, No. 7-8, 01.01.1985, p. 518-524.

Research output: Contribution to journalReview article

Fletcher, C. ; Bean, B. / Evaluation of oral acyclovir therapy. In: Drug Intelligence and Clinical Pharmacy. 1985 ; Vol. 19, No. 7-8. pp. 518-524.
@article{b3d6cb1d4d4848918654c18ee1f3f5c8,
title = "Evaluation of oral acyclovir therapy",
abstract = "Acyclovir is a specific antiviral agent. The triphosphate form inhibits viral DNA replication by competing for incorporation into the replicating DNA chain or by inhibiting viral DNA polymerase. Cells not infected with herpesvirus are generally unaffected. oral acyclovir inhibits most herpes simplex virus types 1 and 2, and varicella-zoster virus at concentrations used clinically. Oral acyclovir has an average plasma half-life of three hours and is eliminated primarily by renal mechanisms. Peak plasma concentrations occur 1.5 to 2.5 hours after administration and the oral bioavailability is 15 to 30{\%}. Acyclovir distributes into most body tissues, including vesicular fluid and the central nervous system. Oral acyclovir is effective treatment of initial and recurrent genital herpes and can suppress frequently recurring genital herpes in both immunocompetent and immunocompromised patients. It is also effective for acute herpes zoster in the immunocompetent and possibly immunocompromised patient. No role is established in either Epstein-Barr virus or cytomegalovirus infections. Oral acyclovir appears to be effective and relatively safe, nontoxic therapy when administered in doses of 1-4 g/d. Oral acyclovir represents a major therapeutic advance in the treatment of herpesvirus infections.",
author = "C. Fletcher and B. Bean",
year = "1985",
month = "1",
day = "1",
doi = "10.1177/106002808501900703",
language = "English (US)",
volume = "19",
pages = "518--524",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "7-8",

}

TY - JOUR

T1 - Evaluation of oral acyclovir therapy

AU - Fletcher, C.

AU - Bean, B.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Acyclovir is a specific antiviral agent. The triphosphate form inhibits viral DNA replication by competing for incorporation into the replicating DNA chain or by inhibiting viral DNA polymerase. Cells not infected with herpesvirus are generally unaffected. oral acyclovir inhibits most herpes simplex virus types 1 and 2, and varicella-zoster virus at concentrations used clinically. Oral acyclovir has an average plasma half-life of three hours and is eliminated primarily by renal mechanisms. Peak plasma concentrations occur 1.5 to 2.5 hours after administration and the oral bioavailability is 15 to 30%. Acyclovir distributes into most body tissues, including vesicular fluid and the central nervous system. Oral acyclovir is effective treatment of initial and recurrent genital herpes and can suppress frequently recurring genital herpes in both immunocompetent and immunocompromised patients. It is also effective for acute herpes zoster in the immunocompetent and possibly immunocompromised patient. No role is established in either Epstein-Barr virus or cytomegalovirus infections. Oral acyclovir appears to be effective and relatively safe, nontoxic therapy when administered in doses of 1-4 g/d. Oral acyclovir represents a major therapeutic advance in the treatment of herpesvirus infections.

AB - Acyclovir is a specific antiviral agent. The triphosphate form inhibits viral DNA replication by competing for incorporation into the replicating DNA chain or by inhibiting viral DNA polymerase. Cells not infected with herpesvirus are generally unaffected. oral acyclovir inhibits most herpes simplex virus types 1 and 2, and varicella-zoster virus at concentrations used clinically. Oral acyclovir has an average plasma half-life of three hours and is eliminated primarily by renal mechanisms. Peak plasma concentrations occur 1.5 to 2.5 hours after administration and the oral bioavailability is 15 to 30%. Acyclovir distributes into most body tissues, including vesicular fluid and the central nervous system. Oral acyclovir is effective treatment of initial and recurrent genital herpes and can suppress frequently recurring genital herpes in both immunocompetent and immunocompromised patients. It is also effective for acute herpes zoster in the immunocompetent and possibly immunocompromised patient. No role is established in either Epstein-Barr virus or cytomegalovirus infections. Oral acyclovir appears to be effective and relatively safe, nontoxic therapy when administered in doses of 1-4 g/d. Oral acyclovir represents a major therapeutic advance in the treatment of herpesvirus infections.

UR - http://www.scopus.com/inward/record.url?scp=0021812649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021812649&partnerID=8YFLogxK

U2 - 10.1177/106002808501900703

DO - 10.1177/106002808501900703

M3 - Review article

C2 - 2992899

AN - SCOPUS:0021812649

VL - 19

SP - 518

EP - 524

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 7-8

ER -